These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 234291)

  • 1. Immunotherapy of melanoma with BCG: two fatalities following intralesional injection.
    McKhann CF; Hendrickson CG; Spitler LE; Gunnarsson A; Banerjee D; Nelson WR
    Cancer; 1975 Feb; 35(2):514-20. PubMed ID: 234291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anaphylactic reaction to intralesional B.C.G.
    Proctor JW; Zidar B; Pomerantz M; Yamamura Y; Eng CP; Woodside D
    Lancet; 1978 Jul; 2(8081):162. PubMed ID: 78369
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe complications of intralesional BCG therapy in an unsensitized patient. Case report and clinical implications.
    Felix EL; Jessup JM; Cohen MH
    Arch Surg; 1978 Jul; 113(7):893-6. PubMed ID: 678104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases.
    Mastrangelo MJ; Bellet RE; Berkelhammer J; Clark WH
    Cancer; 1975 Oct; 36(4):1305-8. PubMed ID: 1175129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma.
    O'Connor TP; Labandter HP; Hiles RW; Bodenham DC
    Br J Plast Surg; 1978 Oct; 31(4):317-22. PubMed ID: 361132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intralesional immunotherapy of melanoma with BCG.
    Rosenberg SA; Rapp HJ
    Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intralesion BCG vaccine therapy in cutaneous melanoma metastasis].
    Wolf M; Menzel W
    Dermatol Monatsschr; 1978 Sep; 164(9):671-2. PubMed ID: 710658
    [No Abstract]   [Full Text] [Related]  

  • 8. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
    Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
    Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma.
    Krown SE; Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Huvos AG; Oettgen HF
    Cancer; 1978 Dec; 42(6):2648-60. PubMed ID: 728866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of immunotherapy in the treatment of malignant melanoma of the skin].
    Kristensen E
    Ugeskr Laeger; 1976 Feb; 138(8):468-73. PubMed ID: 1258215
    [No Abstract]   [Full Text] [Related]  

  • 11. Risks of BCG intralesional therapy: an experience with melanoma.
    Robinson JC
    J Surg Oncol; 1977; 9(6):587-93. PubMed ID: 145518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH; Deutschmann EM; Schultheis W; Deicher H
    Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of systemic BCG therapy in advanced melanoma.
    El-Domeiri AA; Nika B; Hsia WC; Crispen R; Sabet TY; Gupta TK
    Arch Surg; 1977 Mar; 112(3):257-9. PubMed ID: 843215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunology and cutaneous malignant melanoma.
    Sober AJ
    Int J Dermatol; 1976; 15(1):1-18. PubMed ID: 1107238
    [No Abstract]   [Full Text] [Related]  

  • 15. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
    Coates AS; Peters M
    Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epilesional scarification. Preliminary report of a new approach to local immunotherapy with BCG.
    Richman SP; Mavligit GM; Wolk R; Gutterman JU; Hersh EM
    JAMA; 1975 Dec; 234(12):1233-5. PubMed ID: 1242748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCG immunotherapy in patients with malignant melanoma.
    Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED
    Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
    MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
    Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma.
    Nathanson L; Schoenfeld D; Regelson W; Colsky J; Mittelman A
    Cancer; 1979 May; 43(5):1630-5. PubMed ID: 376098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful transurethral intralesional BCG therapy of a bladder melanoma.
    deKernion JB; Golub SH; Gupta RK; Silverstein M; Morton DL
    Cancer; 1975 Nov; 36(5):1662-7. PubMed ID: 1192356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.